Mechanisms of action of statins in stroke

Bibliography

• THE STROKE PREVENTION BY AGGRESSIVE REDUCTION IN CHOLESTEROL LEVELS (SPARCL) INVESTIGATORS: High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med. (2006) 355:549-559.
   PubMed Web of Science ®Google Scholar
• THE 4S INVESTIGATORS: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383-1389.
   PubMed Web of Science ®Google Scholar
• WHITE HD, SIMES RJ, ANDERSON NE et al.: Pravastatin therapy and the risk of stroke. N. Engl. J. Med. (2000) 343:317-326.
   PubMed Web of Science ®Google Scholar
• BYINGTON RP, DAVIS BR, PLEHN JF et al.: Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation (2001) 103:387-392.
   PubMed Web of Science ®Google Scholar
• HEART PROTECTION STUDY COLLABORATIVE GROUP: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 360:7-22.
   PubMed Web of Science ®Google Scholar
• COLLINS R, ARMITAGE J, PARISH S, SLEIGHT P, PETO R; HEART PROTECTION STUDY COLLABORATIVE GROUP: Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet (2004) 363:757-767.
   PubMed Web of Science ®Google Scholar
• TIRSCHWELL DL, SMITH NL, HECKBERT SR et al.: Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology (2004) 63:1868-1875.
   PubMed Web of Science ®Google Scholar
• SEGAL AZ, CHIU RI, EGGLESTON-SEXTON PM, BEISER A, GREENBERG M: Low cholesterol as a risk factor for primary intracerebral hemorrhage: A case-control study. Neuroepidemiology (1999) 18:185-193.
   PubMed Web of Science ®Google Scholar
• KENT DM: Stroke: an equal opportunity for the initiation of statin therapy. N. Engl. J. Med. (2006) 355:613-615.
   PubMed Web of Science ®Google Scholar
• PATTI G, CHELLO M, CANDURA D et al.: Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation (2006) 114:1455-1461.
   PubMed Web of Science ®Google Scholar
• O´DRISCOLL G, GREEN D, TAYLOR RR: Simvastatin, an HMG-CoA reductase inhibitor, improves endothelial function within 1 month. Circulation (1997) 95:1126-1131.
   PubMed Web of Science ®Google Scholar
• HERNANDEZ-PERERA O, PEREZ-SALA D, NAVARRO-ANTOLIN J et al.: Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J. Clin. Invest. (1998) 101:2711-2719.
   PubMed Web of Science ®Google Scholar
• FERON O, DESSY C, DESAGER JP, BALLIGAND JL: Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation (2001) 103:113-118.
   PubMed Web of Science ®Google Scholar
• NIWA S, TOTSUKA T, HAYASHI S: Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int. J. Immunopharmacol. (1996) 18:669-675.
   PubMed Web of Science ®Google Scholar
• TAKEUCHI S, KAWASHIMA S, RIKITAKE Y et al.: Cerivastatin suppresses lipopolysaccharide-induced ICAM-1 expression through inhibition of Rho GTPase in BAEC. Biochem. Biophys. Res. Commun. (2000) 269:97-102.
   PubMed Web of Science ®Google Scholar
• WEBER C, ERL W, WEBER KS, WEBER PC: HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J. Am. Coll. Cardiol. (1997) 30:1212-1217.
   PubMed Web of Science ®Google Scholar
• KIMURA M, KUROSE I, RUSSELL J, GRANGER DN: Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler. Thromb. Vasc. Biol. (1997) 17:1521-1526.
   PubMed Web of Science ®Google Scholar
• SELJEFLOT I, TONSTAD S, HJERMANN I, ARNESEN H: Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis (2002) 162:179-185.
   PubMed Web of Science ®Google Scholar
• BUSTOS C, HERNÁNDEZ-PRESA MA, ORTEGO M et al.: HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J. Am. Coll. Cardiol. (1998) 32:2057-2064.
   PubMed Web of Science ®Google Scholar
• HERNÁNDEZ-PRESA MA, MARTÍN-VENTURA JL, ORTEGO M et al.: Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis (2002) 160:147-153.
   PubMed Web of Science ®Google Scholar
• BARNES PJ, KARIN M: Nuclear factor-κB. A pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. (1997) 336:1066-1071.
   PubMed Web of Science ®Google Scholar
• EGIDO J, HERNÁNDEZ-PRESA MA, TUÑÓN J et al.: Transcription factor κB (NF-κB) and cardiovascular disease. Cardiovasc. Risk Factors (1999) 9:159-168.
   Google Scholar
• AIKAWA M, RABKIN E, SUGIYAMA S et al.: An HMG-CoA reductase inhibitor, cerivastatin, supresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation (2001) 103:276-283.
   PubMed Web of Science ®Google Scholar
• BELLOSTA S, VIA D, CANAVESI M et al.: HMG-Coa reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler. Thromb. Vasc. Biol. (1998) 18:1671-1678.
   PubMed Web of Science ®Google Scholar
• BLANCO-COLIO LM, TUÑÓN J, MARTÍN-VENTURA JL, EGIDO J: Antiinflammatory and immunomodulatory effects of statins. Kidney Int. (2003) 63:12-23
   PubMed Web of Science ®Google Scholar
• CUTTS JL, BANKHURST AD: Suppression of lymphoid cell function in vitro by inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by lovastatin. Int. J. Immunopharmacol. (1989) 11:863-869.
   PubMed Web of Science ®Google Scholar
• KURAKATA S, KADA M, SHIMADA Y et al.: Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacology (1996) 34:51-61.
   PubMed Web of Science ®Google Scholar
• WEITZ-SCHMIDT G, WELZENBACH K, BRINKMANN V et al.: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. (2001) 7:687-692.
   PubMed Web of Science ®Google Scholar
• KWAK B, MULHAUPT F, MYIT S, MACH F: Statins as a newly recognized type of immunomodulator. Nat. Med. (2000) 6:1399-1402.
   PubMed Web of Science ®Google Scholar
• LAUFS U, MARRA D, NODE K, LIAO JK:3-Hydroxy-3-methyl-glutaryl coenzyme a reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced downregulation of p27(Kip1). J. Biol. Chem. (1999) 274:21926-21931.
   PubMed Web of Science ®Google Scholar
• INDOLFI C, CIOPPA A, STABILE E et al.: Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J. Am. Coll. Cardiol. (2000) 35:214-221.
   PubMed Web of Science ®Google Scholar
• CHEN Z, FUKUTOMI T, ZAGO AC et al.: Simvastatin reduces neointimal thickening in low-density lipoprotein receptor-deficient mice after experimental angioplasty without changing plasma lipids. Circulation (2002) 106:20-23.
   PubMed Web of Science ®Google Scholar
• DAVIES MJ: Stability and instability: two faces of coronary atherosclerosis. Circulation (1996) 94:2013-2020.
   PubMed Web of Science ®Google Scholar
• TOSCHI V, GALLO R, LETTINO M et al.: Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation (1997) 95:594-599.
   PubMed Web of Science ®Google Scholar
• NOTARBARTOLO A, DAVI G, AVERNA M et al.: Inhibition of thromboxane biosynthesis and platelet function by simvastatin in Type IIa hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. (1995) 15:247-251.
   PubMed Web of Science ®Google Scholar
• ETO M, KOZAI T, COSENTINO F, JOCH H, LÜSCHER TF: Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation (2002) 105:1756-1759.
   PubMed Web of Science ®Google Scholar
• DANGAS G, BADIMON JJ, SMITH DA et al.: Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J. Am. Coll. Cardiol. (1999) 33:1294-1304.
   PubMed Web of Science ®Google Scholar
• BOURCIER T, LIBBY P: HMG-CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler. Thromb. Vasc. Biol. (2000) 20:556-562
   PubMed Web of Science ®Google Scholar
• CIPOLLONE F, PRONTERA C, PINI B et al.: Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation (2001) 104:921-927.
   PubMed Web of Science ®Google Scholar
• GÓMEZ-HERNÁNDEZ A, MARTÍN-VENTURA JL, SÁNCHEZ-GALÁN E et al.: Overexpression of COX-2, prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis. Regulation by nuclear factor -κB. Atherosclerosis (2006) 187:139-149.
   PubMed Web of Science ®Google Scholar
• JONES CB, SANE DC, HERRINGTON DM: Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc. Res. (2003) 59:812-823.
   PubMed Web of Science ®Google Scholar
• MARTÍN-VENTURA JL, BLANCO-COLIO LM, MUÑOZ-GARCÍA B et al.: NF-κB activation and fas-ligand overexpression in blood and plaques of patients with carotid atherosclerosis: potential implication in plaque instability. Stroke (2004) 35:458-463.
   PubMed Web of Science ®Google Scholar
• CRISBY M, NORDIN-FREDRIKSSON G, SHAH PK et al.: Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation (2001) 103:926-933.
   PubMed Web of Science ®Google Scholar
• CIPOLLONE F, FAZIA M, IEZZI A et al.: Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation (2003) 107:1479-1485.
   PubMed Web of Science ®Google Scholar
• MARTÍN-VENTURA JL, BLANCO-COLIO LM, GÓMEZ-HERNÁNDEZ A et al.: Intensive treatment with atorvastatin reduces blood and plaque inflammation in patients with atherosclerotic lesions in one month. Stroke (2005) 36:1796-1800.
   PubMed Web of Science ®Google Scholar
• BLANCO-COLIO LM, MUÑOZ-GARCIA B, MARTÍN-VENTURA JL et al.:3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors decrease Fas ligand expression and cytotoxicity in activated human T lymphocytes. Circulation (2003) 108:1506-1513.
   Google Scholar
• GÓMEZ-HERNÁNDEZ A, SÁNCHEZ-GALÁN E, MARTÍN-VENTURA JL et al.: Atorvastatin reduces the expression of prostaglandin E2 receptors in human carotid atherosclerotic plaques and monocytic cells: potential implications for plaque stabilization. J. Cardiovasc. Pharmacol. (2006) 47:60-69.
   PubMed Web of Science ®Google Scholar
• TAYLOR AJ, KENT SM, FLAHERTY PJ, COYLE LC, MARKWOOD TT, VERNALIS MN: ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation (2002) 106:2055-2060.
   PubMed Web of Science ®Google Scholar
• CANNON CP, BRAUNWALD E, MCCABE CH et al.: Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. (2004) 350:1495-1504.
   PubMed Web of Science ®Google Scholar
• HANKEY GJ, JAMROZIK K, BROADHURST et al.: Long-term risk of first recurrent stroke in the Perth Community Stroke Study. Stroke (1998) 29:2491-2500.
   PubMed Web of Science ®Google Scholar
• PROSPECTIVE STUDIES COLLABORATION: Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet (1995) 346:1647-1653.
   PubMed Web of Science ®Google Scholar
• BOS MJ, SCHIPPER CM, KOUDSTAAL PJ et al.: High serum C-reactive protein level is not an independent predictor for stroke: the Rotterdam study. Circulation (2006) 114:1591-1598.
   PubMed Web of Science ®Google Scholar
• WANG TJ, GONA P, LARSON MG et al.: Multiple biomarkers for the prediction of first major cardiovascular events and death. N. Engl. J. Med. (2006) 355:2631-2639.
   PubMed Web of Science ®Google Scholar